摘要
目的探讨泰索帝联合顺铂与吉西他滨联合顺铂治疗非小细胞肺癌(NSCLC)的疗效、生存期及毒副作用。方法28例经组织学或细胞学确诊的未曾治疗的晚期非小细胞肺癌(NSCLC),随机分为泰索帝联合顺铂(DC)治疗组(14例)、吉西他滨联合顺铂治疗组(GC)(14例)。结果DC组有效率为42.85%(CR2例,PR4例),一生存率57.1%,中位生存期(MST)8.5个月,TTP5.05个月,中位缓解期(MRT)9.5个月。GC组有效率为38.46%(CRl例,PR4例),一生存率38.5%,中位生存期(MST)8个月,TTP3.89个月,中位缓解期(MRT)8.26个月。WHO血液学毒性评价,Ⅲ/Ⅳ度中性粒细胞下降,DC组:21.4%,GC组:为15.4%;Ⅲ/Ⅳ度血小板减少,DC组:7.1%,GC组:15.4%;Ⅲ/Ⅳ度血红蛋白下降,DC组:7.1%,GC组:7.7%;Ⅱ—Ⅳ度感觉神经病变发生率:DC组:14.3%;GC组:7.7%,;胃肠道反映,Ⅱ/Ⅲ呕吐发生率DC组:(14.3%)明显优于GC组:(53.8%)(P<0.05)。结论DC、GC方案对非小细胞肺癌,显示了相似的有效率,中位生存期及1年生存率。DC组胃肠道反应,Ⅱ/Ⅲ呕吐发生率明显低于GC组,为耐受性较好的治疗晚期NSCLC化疗方案。
Objective To evaluate and compare effects the combination of docetaxel and cisplatin or gemcitabine and cisplatin for the treatment of advanced non--small cell lung cancer（NSCLC） Methods： The 28 cases with non--treatment advanced NSCLC diagnosed by pathologic or cytologic examination were automaticly divided into docetaxel and cisplatin group （DC）（ 14）, gemcitabine and cisplatin groups（GC）（13）, Results：The overall response rate of DC group was 42.85% （CR2, PR4） , one year survival rate was 57.1 % , MST was 8 . 5months , MTTP was 5.05 months, MRT was 9.5 months. For GC group, the overall response rate of this group was 38.46% （CR1, PR4） , one year survival rate was 38.5% , MST was 8 . 0months , MTTP was 3.89 months, MRT was 8.26 months. There were no significant difference in response rate, 1-- ySR,MTTP,MRT and MSTfor these two groups （ P 〉 0.05） . WHO grades 3/4 neutropenia 21.4%in DC groups; 15.4%in GC groups, there were similar in two goups （ P 〉 0.05） . Grade 3/4 anemia occurred 7.1% in DC groups;7.7%in GC groups,The grade 3/4 thrombocyto--penia occured in 7.1% in DC groups;7.7% in GC groups, Nausea/vomiting 14. 3% in DC groups; 7. 7% in GC groups .Conclusion： There were no significant differen in the response of rate, 1--Ysr, MST for two groups. GC might be better chemotherapeutic regi-- ment for advanced NSCLC .
